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Abstract.  A point mutation in a highly conserved re- 
gion of the/3~  subunit, Asp  ~3~ to Ala (D130A)  substitu- 
tion, abrogates the Arg-Gly-Asp (RGD)-dependent bind- 
ing of ot5/3~ to fibronectin (FN) without disrupting gross 
structure or heterodimer assembly. The D130A muta- 
tion also interferes with binding to invasin, a ligand 
that lacks RGD sequence. In spite of the lack of detec- 
table FN binding by cts/3~(D130A), it was recruited to 
adhesion plaques formed on FN by endogenous hamster 
receptors. Thus, intact ligand binding function is not 
required for recruitment of c~5/3~ to adhesion plaques. 
Overexpression of/3~(D130A) partially interfered with 
endogenous tXsl3~ function, thus defining a dominant 
negative/3~  integrin mutation. 
T 
HE integrins comprise a  family of at least six het- 
erodimers of cell surface receptors which share com- 
mon/3t subunits  but have distinct o~ subunits.  They 
recognize multiple ligands (for review see Hemler, 1990) in- 
cluding  fibronectin  (FN) ~,  laminin,  collagen,  epiligrin 
(Carter et al., 1991), invasin (Isberg and Leong, 1990), and 
vascular cell adhesion molecule-1 (Elices et al., 1990), and 
mediate cell-cell and cell-extracellular matrix interactions. 
The identification of the ligand binding domain of/3~ inte- 
grins is important for understanding their functions. Chemi- 
cal cross-linking studies of Arg-Gly-Asp (RGD)-containing 
peptides to the RGD-dependent  t33 integrins,  platelet  ~r0~33 
(GPIlb-llIa) and o~vt33 (vitronectin  receptor), have shown 
that RGD-containing peptide cross-links to residues 109-171 
of/33 of Ot~ro/33 (D'Souza et al., 1988), and to an overlapping 
region (residues 61-203) of the/33 of o~v/33 (Smith and Cher- 
esh, 1988). In addition,/33 of C~ro/33 from a thrombasthenic 
patient has a point substitution at Asp u9 to Tyr, which inac- 
tivates ot~rd3~  binding to fibrinogen (Loftus et al., 1990), un- 
derscoring the importance of this region in ligand-/33 inte- 
grin interaction. 
Based  on  the  high  similarity  of this  region  (residues 
109-171  of/3t) among integrin 13 subunits,  especially the 
smaller region consisting of residues 108-127 (76 and 81%, 
respectively), compared to overall similarity  (•45%),  we 
hypothesized that the corresponding region in/3~ is also in- 
volved in the ligand-/3~ integrin interaction. To address this 
hypothesis,  we examined the effects of the substitution  of 
Asp  ~3~ of/3~ (which corresponds to the Asp  H9 in/33) to Ala 
(D130A substitution)  on t~5/3t functions,  ots/3~ binds  to the 
110K cell binding domain of FN in an RGD-dependent man- 
ner (Pytela et al., 1985), as well as to invasin, a protein in- 
1. Abbreviations used in this paper: DHFR, dihydrofolate reductase;  FN, 
fibronectin; MBP-Inv479, maltose binding protein-invasin  fusion protein. 
volved in the entry of the bacterial cells into eukaryotic cells 
(Isberg and Leong, 1990). The affinity of ot5/3~ for invasin is 
two orders of magnitude higher than for FN (Isberg,  1991; 
Nrhieu and Isberg,  1991). In addition,  the COOH-terminal 
192 amino acid residues of invasin, which contain the inte- 
grin binding region, do not contain RGD sequence. 
We  report here that the  D130A substitution  in  the /3~ 
subunit  blocks  the binding  of c~513~ both to the FN  ll0K 
cell binding  fragment and to  invasin.  Overexpression  of 
/31(D130A) interfered with the endogenous  ot5/31 function. 
Furthermore, ligand-binding  defective /3~(D130A) was as- 
sembled into the adhesion plaques  formed in transfected 
cells cultured on Fn, suggesting that intact ligand binding is 
not essential for the recruitment of this receptor to existing 
adhesion plaques. 
Materials and Methods 
Materials 
FN was purified from fresh human plasma by using gelatin Sepharose (Eng- 
val and Ruoslahti,  1977; Plow et al.,  1979). FN I10K fragment was ob- 
tained by chymotryptic digestion of FN and subsequent gelatin-Sepharose 
and Sephacryl S-200 gel filtration chromatographies  (Pierschbacher et al., 
1982). MBP-Inv479 was prepared by using pJL309 plasmid in Escherichia 
coli MC1000 which was provided by R. Isberg (Tufts University, Boston, 
MA) (Leong et al, 1990). FN IlOK fragment and MBP-Inv479 was cou- 
pled to CNBr-activated  Sepharose  (Pharmacia  LKB Biotechnology  Inc., 
Piscataway, NJ) at 2.4 and 2.0 mg/ml packed volume, respectively, accord- 
ing to the manufacturer's instructions.  PMSF and octyl-/3-D-glucopyrano- 
side were purchased from Caibiochem Corp. (La Jolla, CA). N-Ethylmalei- 
mide was purchased from Sigma Chem. Co. (St. Louis, MO), and Na125I 
from Amersham Corp.  (Arlington  Heights, IL). 
mAb 7E2 (to hamster/30 and PB1 (to hamster cts) (Brown and Juliano, 
1985, 1988) were from R. L. Juliano (University of North Carolina, Chapel 
Hill, NC). mAbs to human ~i were obtained from the following sources: 
AlAS from M. E. Hemler (Dana-Farber  Cancer Institute,  Boston,  MA); 
mAbl3 (Akiyama et al., 1989) from K. Yamada (NIH, Washington, DC); 
LM534 (Cheresh et al., 1989) from D. Cheresh (The Scripps Research In- 
￿9  The Rockefeller University Press, 0021-9525/92/11/913/9 $2.00 
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stitute).  102DF5 was prepared as described (Yliinne and Virtanen,  1989). 
Goat anti-human ~1 antiserum (antibody 172) was prepared by immuniz- 
ing a goat with purified human a4/~l  preparation,  and recognizes human 
but not hamster #1.  Anti-denatured ~1 antiserum (cross-reactive to both 
human and hamster/~t) was prepared by immunizing rabbits with the SDS- 
denatured at/31 preparation purified from human placenta (Takada et al., 
1987).  The serum recognizes human al and/31, and mouse and hamster 
fit. Anti-a3 cytoplasmic peptide antibody (reactive to human, mouse, and 
chicken a3 [Solowska et al.,  1989; Takada et al.,  1991]) and anti-as cyto- 
plasmic  peptide  antibody  were  obtained  from  E.  Mareantonio  (Mas- 
sachusetts Institute of Technology, Cambridge,  MA).  The anti-denatured 
human a4 antibody  (reactive to human and mouse a4  [Holzman et al., 
1989]),  was prepared as described (Hemler et al.,  1987;  Takada  et al., 
1989).  The  anti-c~2 cytoplasmic  peptide  antibody  was  prepared  as  de- 
scribed (Takada and Hemler,  1989). 
Construction of ~l cDNA Expression Vector 
and Mutagenesis 
The human ~1  cDNA  clone  (B-3)  was  cloned from human endothelial 
Xgtll library (obtained from T. Collins, Brigham and Women's Hospital, 
Boston, MA) with partial/31 cDNA (obtained from E. Ruoslahti, La Jolla 
Cancer Research Foundation, La Jolla, CA) as probe. The clone B-3 (•3.55 
kb) includes a 2,334-bp complete coding region, and 58-bp 5'-noneoding 
and 1,100-bp 3'-noncoding regions. The amino acid sequence deduced from 
the nucleotide sequence of the clone B-3 was the same as the published se- 
quence (Argraves et al.,  1987) except that His  92 was Thr and Thr  19s was 
Ser in clone B-3. Oligonucleotide-direeted mutagenesis of/~1 eDNA clone 
B-3 in pBluescript KS+ was carded out using a combination of the primer 
extension method (Zoller and Smith,  1982), and the method of Kunkel et 
ai.  (1987) with synthetic oligonucleotide, 5'-ACTACCTTATGGCCCTGT- 
CTTATTC-3' (YLMALSYS) based on the published/~1 sequence 5'-ACT- 
ACCTTATGGACCTGTCTTATTC-3' (YLMDLSYS) as primer. The whole 
coding region of the mutagenized eDNA was sequenced and the absence 
of other mutations was confirmed.  The wild-type/~1  or mutagenized #~ 
(D130A) eDNA in pBluescript was digested with XbaI (XbaI site is in the 
vector) and NheI (NheI site is in a 3' noneoding region in eDNA).  After 
gel purification, the 2.9-kb XbaI/NheI fragment containing whole coding 
region  was  ligated  to  XbaI-digested/caif  intestinal  phosphatase-treated 
pCDneo vector (Aruffo and Seed,  1987). 
Transfection and Amplification of the 
Transfected Gene 
DG44 cells, a dihydrofolate reductase (DHFR)-deficient mutant of CHO 
cell line (Urlaub and Chasin, 1980) (obtained from L. A. Chasin, Columbia 
University,  NY),  were  maintained  in the  a-modified  minimal essential 
medium (a-minus MEM, Sigma Chem. Co.) supplemented with 10% heat- 
inactivated FCS,  hypoxanthine, and thymidine in a 5 % CO2 incubator at 
37~  ~1  or /31(D130A)  cDNA  in pCDneo  vector  (10  /~g) and  1 /~g of 
pLTRdhfr26 plasmid (Subramani et ai.,  1981) (obtained from Amer. Type 
Culture Collection,  Rockville,  MD)  were cotransfected into DG44 cells 
(107 cells) by electroporation. Transfected cells were maintained for 3 d in 
the above medium, and then transferred to a-minus MEM supplemented 
with 10% dialyzed FCS and 700/~g/ml G418 (Gibco Laboratories, Grand 
Island, NY). After 10-14 d, resulting colonies were harvested and cells ex- 
pressing human/3x were collected by sorting with mAb A1A5 in FACStar 
(Becton Dickinson Immunocytometry  Sys.,  Mountain View,  CA).  mAb 
AlAS reacts with both human/31 and/31(D130A)  (Fig.  1, e  and f).  The 
transfected genes were then amplified in a-minus MEM supplemented with 
10% dialyzed FCS, 700 #g/ml G418, and the increasing concentration (up to 
100 nM) of the DHFR inhibitor methotrexate (Kaufman and Sharp, 1982). 
FN IIOK Fragment-Sepharose 
Affinity Chromatography 
Cells were harvested by washing the attached cells with PBS (0.15 M NaC1, 
10  mM  potassium phosphate,  pH  7.4) twice and incubating in 3.5  mM 
EDTA in PBS at room temperature for 3 rain, and washed twice with PBS. 
Cells  ("~  ￿  106) were then surface labeled with  t25I by using iodogen 
(Pierce Chem., Rockford, IL) (Braciale et ai.,  1986), washed three times 
with PBS, and solubilized in 0.4 ml of 100 mM octyl-/3-D-glucopyranoside 
in 10 mM Tris-HCl/0.15 M  NaC1 (TBS),  1 mM MnC12,  1 mM PMSE  1 
mM N-ethylmaleimide, pH 7.4, at 4~  for 1 h. The insoluble materials were 
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Figure 1. The expression  of human ~1 or/3~(D130A) in CHO cells. 
The/3~-,/31(D130A)-, or parent CHO cells were harvested and in- 
cubated with the first antibodies  (a-c, control purified mouse IgG 
[10 #g/ml];  d-f,  A1A5  [anti-human  ~];  g-i,  7E2  [anti-hamster 
/3~]; or j-l, PB1 [anti-hamster  as]), and then with the FITC-labeled 
goat anti-mouse IgG.  Ascites A1A5,  7E2,  and PB1  were diluted 
500-fold  and used.  The stained  cells  were analyzed by FACStar 
(Becton Dickinson Inununocytometry  Sys.) The mean fluorescent 
intensities were (a) 4.1, (b) 14.2, (c) 15.1, (d) 5.2, (e) 168, (f) 174, 
Q) 221,  (h) 210,  (i) 98.4,  (j)  170,  (k)  174, and (l)  168. 
removed by centrifugation at 15,000 g for 10 min. The supernatant was then 
incubated with a small amount of underivatized Sepharose 4B at 4~  for 
1 h to remove nonspecific binding material. The supernatant was incubated 
with 1 ml of packed FN ll0K fragment-Sepharose at 4~  overnight, which 
had been equilibrated with TBS containing 1 mM MnCI2,  i  mM PMSF, 
1 mM N-ethylmaleimide, 25 mM octyl-~-D-glucopyranoside, pH 7.4 (wash- 
ing buffer).  The unbound materials were washed with 20 ml of washing 
buffer and the bound materials were eluted with 20 mM EDTA instead of 
1 mM MnC12 in washing buffer, and 2.5-ml fractions were collected. 0.25- 
ml aliquots of the peak fraction (2.5 ml) of the eluted radioactivity were 
used for immunoprecipitation. The samples were precleared by incubating 
with protein G-Sepharose and immunoprecipitated as described below. 
Maltose Binding Protein-Invasin 
Fusion Protein (MBP-Inv479)-Sepharose 
Affinity Chromatography 
The MBP-Inv479-Sepharose affinity chromatography was carried out as de- 
scribed above for FN ll0K-Sepharose chromatography except that (a) 50 
/~1  packed  volume  of  MBP-Inv479-Sepharose  was  used,  (b)  unbound 
materials were removed by washing three times in 1 ml of washing buffer, 
and (c) 500/~1 of 20 mM EDTA in washing buffer was used for elution. 
Immunoprecipitation of CeU Extracts 
Cells were 12sI surface-labeled, and washed as described above and solubi- 
lized in 1 ml of 20 mM Tris, 0.15 M NaCI,  1% Triton X-100, 0.05% Tween 
20, pH 7.4, containing 2  mM PMSF,  10 mM benzamidine HC1,  5  U/ml 
trasylol,  and 0.02 %  NaN3  (IPB),  and incubated on ice for  1 h  and cen- 
trifuged at 15,000 g for 10 min. The supernatant was precleared by incubat- 
ing with protein G-Sepharose (Pharmacia LKB Biotechnology Inc.) for 30 
min at 4~  and incubated with antibody for 1 h at room temperature. The 
immune complex was recovered by incubating with protein G-Sepharose 
for 30 min at 4~  washed three times with 1 ml IPB, boiled for 5 min in 
50 #1 of SDS-PAGE sample buffer, and analyzed by SDS-PAGE (7% gel) 
(Laemmli,  1970) under nonreducing conditions. 
Adhesion of CeUs to FN-coated Plates 
Wells of the Immulon 2 removable 96-well plates (Dynatech Labs.,  Inc., 
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centrations  of FN overnight at 4~  The other protein binding sites were 
blocked by incubating with 100 #1 of 1% BSA for 30 min at room tempera- 
ture,  and wells were washed twice with PBS. Cells were harvested  with 
TPCK trypsin  (Worthington  Biochem.  Corp.,  Freehold,  NJ),  3.5  mM 
EDTA in PBS,  washed once with  0.5  mg/ml  soybean trypsin  inhibitor 
(Sigma Chem.  Co.),  and washed twice with incubation buffer (137.5 mM 
NaCl,  12 mM NaHCO3, 2.6 mM KC1, 5 mM Hepes,  5 mM glucose,  2 
mM CaC12, 0.1% BSA). 3  x  106 cells in 200/zl incubation buffer were in- 
cubated with 50 #Ci NaStCr (12.5-25  Ci/mmol, Amersham Corp.) for 1 h 
at 37~  and washed three times with incubation buffer. 4  x  104 cells (100 
/xl) were added to each well and incubated for 1 h at 37~  The wells were 
washed three times with incubation buffer and then bound radioactivity was 
counted in a ~/counter. 
Indirect Immunofluorescence  Microscopy 
Cells were harvested with 0.05 % trypsin, 0.5 mM EDTA (Irvine Scientific, 
Santa Ana, CA); washed once with tx-minus MEM supplemented with 10% 
FCS, hypoxanthine, and thymidine; and then twice with the medium minus 
serum. Round glass coverslips were coated overnight at 4"C with 20/zg/ml 
of FN in PBS; then the other protein binding sites were blocked by incubat- 
ing with 1% BSA for 30 rain at room temperature. The harvested cells were 
plated onto the coverslips in the medium minus serum,  incubated for 4 h 
at 37~  and then fixed with methanol for 10 min in -20~  The number 
of spreading cells were counted from three high power microscopic fields 
(28-144 cells were counted in each field). The fixed cells were incubated 
with the primary antibodies, and then with FITC-coupled goat anti-mouse 
IgG ('lhgo, Inc.,  Budingame,  CA),  for 30 min at room temperature.  The 
stained cells were observed in an Axiophot fluorescent microscope  (Carl 
Zeiss, Inc.,  Oberkochen,  Germany). 
Results 
Expression and Characterization  of Human 131 or 
131(D13OA) in CHO Cells 
The  /3~  or  /3~(D130A)  cDNA  was  transfected  into  CHO 
cells.  After  selection  by  resistance  to  G418  and  DHFR § 
phenotype,  human/3t  or/3~(D130A)  expression was  further 
amplified by using increasing methotrexate,  a DHFR inhibi- 
tor,  concentration  in the medium.  Human/3~  or/3~(D130A) 
was expressed at levels approximately equal to that of endog- 
enous  hamster  /3~  in  CHO  cells  (Fig.  1).  Both  /31  and 
/3~(D130A)  were  recognized  by  four  other  anti-human  /31 
mAbs,  in addition to A1A5-mAbl3,  LM534,  QE.2E5,  and 
102DF5-but  none  of these mAbs  recognized the endoge- 
nous  hamster/31  (data  not shown). 
Immunoprecipitations  of the  ~25I surface-labeled  cell ex- 
tracts  (Fig.  2)  showed that the human/31  or/3t(D130A)  (Mr 
Figure  2.  Immunoprecipitation  of hu- 
man/31- or/31(D130A)-CHO ceils. The 
detergent  extracts  of the  ~25I surface- 
labeled  CHO  cells  (lanes  1-6),  131- 
(lanes  7-12),  or  /31(DI30A)-  (lanes 
13-18) CHO cells were immunoprecipi- 
tated with mAb PB1  (anti-hamster  c~5) 
(lanes 1, 7, 13), mAb 7E2 (anti-hamster 
/3~ (lanes 2, 8, 14), mAb A1A5 (lanes 3, 
9,  15),  anti-denatured  /31  (nonspecies 
specific (lanes 4, 10, 16), antibody  172 
(anti-human  /31) (lanes  5,  11,  17),  or 
rabbit  preimmune  serum  (lanes  6,  12, 
18). The immunoprecipitated materials 
were analyzed by SDS-PAGE (7 %  gel) 
under nonreducing conditions. 
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as in CHO cells. A detergent extract of ~I surface-labeled/35- or 
/3~(D130A)-CHO  cells  was  first  immunopurified  with  human 
~3~-specific AIA5-Sepharose overnight at 4~  After washing the 
A1A5-Sepharose, the bound materials were recovered by boiling in 
SDS-PAGE sample buffer containing  1% (wt/vol) SDS for 5 rain. 
The recovered material was diluted fivehold with IPB (see Mate- 
rials  and  Methods),  and again immunoprecipitated  with  anti-c~5 
cytoplasmic peptide antibody (lanes 1 and 5),  anti-denatured  aa 
polyclonal antibody (lanes 2 and 6), anti-c~3 cytoplasmic antibody 
(lanes 3 and 7), or anti-denatured/3~ polyclonal antibody (lanes 4 
and  8).  The immunoprecipitated materials were analyzed as de- 
scribed in the legend of Fig.  1. 
ll0K,  nonreduced)  associated with endogenous  hamster ct 
subunits  (Mr  150K,  nonreduced)  in both B~-CHO (lanes  9 
and  1/)  and  t3~(D130A)-CHO  (lanes  15  and  17).  Anti- 
denatured  /3~  recognized  both  hamster  Bt  and  human 
t3t//Jt(D130A)  (lanes  4,  10,  and  16).  Antibody  172  recog- 
nized human/3J/3ffD130A)  but not hamster B~ (lanes 5,  11, 
and  17). 
We undertook studies to identify the ot subunit associated 
with  the  recombinant  human  /3~//3~(D130A).  CHO  ceils 
contain  aSBl  as the major/31  integrin  species  with  a  small 
amount  of ot3/3t (Giancotti  and  Ruoslahti,  1990).  o~5-defi- 
cient  CHO  cells  lose  ,~80%  of  /3t  integrin  expression 
(Schreiner  et  al.,  1989),  and  CHO  cells  express  similar 
quantities of ot~ and/~  (Fig.  1). Consistent with these, c~ or 
a2 (which are larger in size than other a  subunits)  was not 
detected in CHO cells by immunoprecipitation  with anti431 
(Fig.  2)  or  anti-c~2  cytoplasmic  peptide  antibody  (Takada 
and Hemler,  1989) (Fig.  4,  lanes 15 and 21). To determine 
whether  the  transfected  human  /31  or  B~(D130A)  is  as- 
sociated  with  a5  and/or  c~3, extracts  of surface  ~2SI-labeled 
transfected  cells  were  immunopurified  with  human 
/3~-specific mAb A1A5  immobilized to Sepharose.  The re- 
covered recombinant/Jr  integrins were solubilized and then 
reimmunoprecipitated with antibodies that react with multi- 
ple species ~  subunits.  The anti-as cytoplasmic domain an- 
tibody precipitated  the ot subunit associated with human/3t 
Figure 4. Ors[31 but not ~5/3~(D130A) binds to cell-binding domain of FN. Detergent extracts of t251 surface-labeled CHO cells bearing c~s/3~ 
or c~5/~(D130A) were passed through immobilized FN  l l0K  (central cell-binding domain) affinity columns as described in Materials 
and Methods.  250-/~1 aliquots of the peak EDTA-eluted fraction (2.5 ml) from the FN  ll0K Sepharose column with/3~  (lanes 1-7) or 
B~(D130A) (lanes 8-14) CHO extract, or the peak pass-through fraction (2.5 ml) with/31 (lanes 15-20) or/31(D130A) (lanes 21-26) CHO 
extract were analyzed by immunoprecipitation with anti-human/3~ polyclonal (172) (lanes 3, 10, 16 and 22) or monoclonal A1A5 (lanes 
4, 11, 17 and 23) antibodies; anti-hamster t~5 monoclonal (PB1) (lanes 5 and 12); anti-hamster/31 monoclonal (7E2) (lanes 6, 13, 18 and 
24); anti-denatured/3~  (nonspecies-specific) polyclonal (lanes 7, 14, 19 and 25); or irrelevant polyclonal antibody (antiintegrin ct2 cyto- 
plasmic domain) (lanes 2, 9, 15 and 21). The EDTA-eluted material (20 #1 each) from the FN  ll0K-Sepharose with/Jr- or/31(D130A)- 
CHO extract were also analyzed without immunoprecipitation (lanes 1 and 20, and 8 and 26, respectively). The samples were analyzed 
by SDS-PAGE (7% gel) under nonreducing conditions.  (Lanes 1-14) The EDTA eluate from/31-CHO contained hamster c~5 and O~, and 
human/3~. The eluate from the/3,(DI30A)-CHO contained hamster or5 and/3~,  but no human/31(D130A).  (Lanes 15-26) The human ~3t 
and B~(D130A) were present in the unbound  fractions. 
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tectable immunoprecipitates (Fig. 3). Thus, the recombinant 
human ~,  or ~(D130A)  was  associated with endogenous 
hamster o~s. 
a~[3~(DI3OA  ) Does Not Bind to FN IIOK Fragment 
The previous experiments established that both human/~ 
and/3~(D130A)  were expressed as heterodimers with ham- 
ster o~.  Since FN is a major ligand for ot~#~, we assessed 
the binding of these recombinants to the immobilized cell 
binding  domain  of  FN.  When  extracts  of  surface  ~2~I- 
labeled CHO cells bearing recombinant/31 integrins were 
subjected to FN ll0K affinity chromatography, the bound 
fraction (EDTA eluate) contained only two ~2~I-labeled  pro- 
tein bands corresponding to c~ and 151 subunits in size (Mr 
150K  and  ll0K, nonreduced) (Fig. 4,  lanes 1  and 8,  for 
~t-CHO and ~(D130A)-CHO  cells,  respectively). Immu- 
noprecipitation of the EDTA eluate (Fig. 4) showed that the 
eluate from ~:CHO contained hamster o~ (lane 5) and ham- 
ster (lane 6) and human (lanes 3 and 4) ~. The eluate from 
the ~(D130A)-CHO contained hamster o~ (lane 12) and ~ 
Oane 13), but no human/3~(D130A)  (lanes 10 and 11). The 
human ~  and  /3~(D130A) were  detected in  the unbound 
fractions by immunoprecipitation (Fig. 4, lanes 16 and 17; 
22 and 23, respectively). Thus, c~B~(D130A) had no detect- 
able affinity for the FN ll0K fragment. 
~d3~(D13OA) Does Not Bind to Invasin 
FN binding to otsfll depends on the RGD sequence in the 
10th type HI repeat (Pytela et al., 1985; Pierschbacher et al., 
1982; Obara et al., 1988). To determine whether the D130A 
substitution abolished binding to a ligand that lacks RGD, we 
assessed the binding of ots~(D130A)  to  invasin.  The  ~25I 
surface-labeled  cell  extracts  were  incubated  with  MBP- 
Inv479-Sepharose  in  the  presence  of  Mn  :+.  SDS-PAGE 
analysis of the EDTA eluted materials detected two bands 
corresponding to c~ and ~  in size (Fig. 5). The EDTA elu- 
ates were analyzed  by immunoprecipitation (Fig. 5, bottom). 
Both human and hamster ~  (lanes 3  and 4,  respectively) 
were detected with wild-type ~t-CHO cells, while hamster 
~  (lane 9), but no human ~t(D130A),  was detected (lane 8) 
with the B~(D130A)-CHO cells.  These findings show that 
D130A substitution of/~ subunit blocks the binding of ~s/3t 
to invasin. 
Figure 5. ots[3~ but not cts~(D13OA) binds to MBP-Inv479-Sepha- 
rose. (Top) Immunoprecipitation of 200 #1 of the same detergent 
extract of/$1- (lane 1) or ~(D13OA)-CHO (lane 2) cells as in Fig. 
2 by AIA5 (human-specific anti-B0.  The detergent extracts were 
incubated with 50 #1 of MBP-Inv479-Sepharose in the presence of 
1 mM Mn  2+, and washed; and the bound material was eluted with 
20 mM EDTA in the column buffer (lanes 3 and 4). Samples were 
analyzed by SDS-PAGE (7% gel) under nonreducing conditions. 
The density of two bands of Mr '~110 kD and 150 kD was lower 
with ~ffD130A)-CHO  ceils in four separate experiments (lane 4). 
(Bottom) The bound fraction (Fig. 5, top) from ~  (lanes 1-5) or 
Bt(D130A) (lanes 6-10) immunoprecipitated with preimmune rab- 
bit serum (lanes 2 and 7); antibody 172 (lanes 3 and 8); mAb 7E2 
(lanes 4 and 9); and anti-denatured/3t (lanes 5 and 10). 20 #1 each 
of the EDTA fraction from/3,- or B~(D130A)-CHO ceils was ana- 
lyzed without immunoprecipitation in lanes 1 and 6, respectively. 
Samples were analyzed by SDS-PAGE (7% gel) under nonreducing 
conditions. 
Overexpression of ~z(D130A ) Produces Dominant 
Negative Effects 
~(D130A) forms a binding-defective heterodimer with en- 
dogenous or5 and may, therefore, block cell functions de- 
pendent on ots/~. To test this possibility, the adhesion of/~I- 
CHO or/~(D130A)-CHO cells to FN was examined (Fig. 
6).  The ~(D130A)-CHO  cells were less  adherent to  FN 
than the ~-CHO or parent CHO cells (the amount of FN 
required  for 50%  of cells to  adhere was 0.2  #g/well for 
~(D130A)-CHO  cells  and  0.1  #g/well  for  the  others), 
reflecting the decrease in functional as/~t on the surface. At 
higher FN concentration (2 #g/well), the difference in adhe- 
sion among parent, B~-CHO, and #t(D130A)-CHO cells is 
relatively small.  However,  only 7.4  +  1.5%  of adhering 
/3~(DI30A)-CHO  cells spread in contrast to 56  +  7.5 and 
46  5:  8.1% of adherent CHO and ~-CHO  cells,  respec- 
tively. Fig. 7 shows the striking difference in morphology be- 
tween  human  /~  and  /3~(D130A) CHO  cells  on  FN  (2 
#g/well).  Thus, overexpression of ~(D130A)  reduces the 
function of endogenous as/~.  The  ratio of expression of 
B1(D130A) mutant to endogenous wild-type ~  integrin in 
/$~130A)-CHO cells was ",,2:1 based on the mean fluores- 
cent intensity (Fig.  1). 
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Figure 6.  ~t(D130A)-CHO cells were less adherent to FN than 
CHO or B~-CHO cells. Wells of the removable  96-well plates were 
coated with varying concentrations of FN. 4  x  104 5'Cr-labeled 
ceils (100/~1) were added to each well and incubated for 1 h at 37~ 
The wells were washed three times with incubation buffer and then 
bound radioactivity was counted. Data are shown  as means of  tripli- 
cate  experiments  +  SD.  CHO  (o),  /31-CHO (e),  ~I(D130A)- 
CHO (A). 
Binding-defective Human ~(DI3OA ) Is Assembled into 
Adhesion Plaques on FN 
As  noted  above,  a  small  percentage  of ~t(DI30A)-CHO 
cells spread on FN. To determine whether this ligand bind- 
ing-defective mutant could be recruited to adhesion plaques 
formed by endogenous hamster t~5~,  we localized the hu- 
man/3~ or ~t(D130A)  in the transfectants that spread on the 
FN-coated glass coverslips (Fig. 8). In/3~-CHO cells, ham- 
ster  /~  (mAb  7E2,  b)  and human /3t  (mAbs  102DF5,  e; 
QE.2E5, h; A1A5, k; LM534, data not shown) were local- 
ized in the adhesion plaques. In the spreading/~(D130A)- 
CHO cells, human /3~(D130A) mutant was present in the 
adhesion plaques as detected by three antihuman/3~ mAbs 
(102DFS, f; QE.2E5, i; LM534, data not shown). This stain- 
ing was specific for human/31, since these three antibodies 
did not stain the hamster/3t-containing adhesion plaques 
formed by untransfected CHO cells (Fig. 8, d and g; data not 
shown for LM534).  Surprisingly, the antihuman ~1, A1A5 
did not stain the plaques in the/3~(D130A)-CHO  cells (Fig. 
8 l). Essentially, the same results were obtained also with 
CHO cells transiently expressing human/3~ or/3t(D130A) 
subunit on the surface after 48 h of transfection (data not 
shown). These findings indicate that/3~(D130A) mutant can 
be recruited to adhesion plaques formed by hamster c~5/3,. 
Discussion 
This paper establishes that a point mutation in a highly con- 
served region of the/~ subunit (Asp ~3~ to Ala substitution) 
abrogates the RGD-dependent binding of t~5/3~ to FN, and 
that the substitution also interferes with the recognition of in- 
vasin  that  lacks  the  RGD  sequence,  suggesting  that  the 
Asp  13~ is critical in multiple ligand-o~5/~ interactions. The 
Asp  '3~ to Ala substitution of/3~ does not result in a major 
structural  change  in  the  whole  ~  molecule because  (a) 
~](D130A)  was expressed on the surface of CHO cells in 
association with endogenous o~5 subunits, and (b) five mAbs 
against human ~l  recognize ~(D130A).  Thus, the D130A 
mutation in ~  abrogates a5/3~ ligand binding function with- 
out disrupting gross structure or heterodimer assembly. 
Asp ~3~  of/3~ corresponds to Asp  ~'9 of ~3, a residue reported 
to be critical in ligand (fibrinogen) binding to ot~n,/3a (Loftus 
et al.,  1990).  Since the protein ligands of Ol~rd3a contain 
RGD sequences, it is noteworthy that u5~(D130A) failed to 
recognize invasin, a ligand which lacks the RGD sequence 
(Isberg and Leong, 1990).  Nevertheless, the binding of in- 
vasin to ol5/3~ is inhibited by RGD peptide (Nhieu and Is- 
berg,  1991). Taken together, these data are consistent with 
a common ligand binding mechanism for integrins irrespec- 
tive of the presence of the RGD sequence in the ligand. The 
high degree of conservation of the  sequence  surrounding 
Asp ~3~ is consistent with such a mechanism (Loftus et al., 
1990). 
Although a5/3~(D130A) was  ligand binding defective, it 
was recruited into adhesion plaques on FN.  This suggests 
that integrins can be recruited to adhesion plaques without 
binding ligands. Clustering of individual receptors and orga- 
nization thereafter occurred only when cells were exposed 
to the specific ligand and the clustering preceded the associa- 
tion of  vinculin with adhesion plaques and stress fiber forma- 
tion (Dejana et al.,  1988).  Chicken B] lacking cytoplasmic 
domain does not enter adhesion plaques; however,  it does 
bind to FN,  suggesting that interaction with cytoskeletal 
components is necessary for the localization of the receptors 
to adhesion plaques (Solowska et al., 1989). Therefore, one 
possible sequence of events in the localization of receptor in 
adhesion plaques is (a) the interaction of the receptor with 
the  specific  matrix  protein  ligand,  (b)  clustering  of the 
specific receptor species, and then (c) the interaction with 
cytoskeletal components. One possible explanation for the 
localization of binding-defective ots/3~(D130A) in adhesion 
plaques is that the initial interaction of intact hamster ~5/3~ 
with FN induces clustering of the receptors, including both 
as~] and oLs~(D130A), leading to the incorporation of the 
~L(D130A)  into  adhesion  plaques.  Consistent  with  this, 
LaFlamme et al.  (1992) suggested that fl~ cytoplasmic do- 
main  has  enough  information to  target  Otsfll to  existing 
adhesion plaques, since IL-2 receptor with/3~ cytoplasmic 
domain was recruited to existing adhesion plaques on FN. 
However,  we could not rule out the possibility that there 
could be  some interaction of the  asfl~(D130A) with FN, 
leading to FN-dependent conformational changes, which al- 
low for the recruitment of fl~(D130A) to focal adhesions. 
LaFlamme et al.  (1992) also suggested that the ligand oc- 
cupancy regulates the redistribution of the receptor via con- 
formational change that unmasks the  fl~  cytoplasmic do- 
main or regions of the cytoplasmic domain that interact with 
specific cytoskeletal proteins, since RGD peptide promoted 
the recruitment of o~sfl~ into adhesion plaques on laminin, 
an irrelevant ligand. Because ligand binding-defective c~fll- 
(D130A) was recruited to adhesion plaques, it might have a 
conformation similar to that of a ligand-occupied form. 
/3~(D130A) is detected in adhesion plaques of the trans- 
fected CHO cells cultured on FN with four different anti- 
The Journal of Cell Biology,  Volume 119, 1992  918 Figure 7. 13t-CliO  cells spread  on FN but t3t(DI30A) 
CHO cells do not. Wells of  the 96-well  plates were 
coated with 100/~1 of 20 ~g/ml FN in PBS. 4  ￿ 
I04 unlabeled cells (100/~1) were added to each 
well and incubated for l h at 37~  Pictures were 
taken without washing the unbound cells. Details 
are described in Materials and Methods. (/bp) Hu- 
man wild-type /31-CHO cells. (Bottom) Human 
/3ffD130A) CHO cells. 
human/32 mAbs but, not with mAb A1A5. One possible ex- 
planation of this data is that A1A5 epitope in t31 is related to 
a site of receptor-receptor interaction during clustering and, 
therefore, its epitope is not accessible to antibody in adhe- 
sion  plaques  formed  in  131(D130A)-CHO cells  because 
recruitment of/31(D130A) to adhesion plaques is dependent 
on interactions that shield the epitope. In contrast, wild-type 
human i31 may also be recruited by ligand binding and may 
express accessible A1A5 epitopes. 
The ability to delete ~31 integrins would be very helpful 
for defining their roles in adhesion, migration, differentia- 
tion, metastasis, transformed phenotype, or signal transduc- 
tion.  Almost all cell lines express/31  integrins in various 
combinations (for review see Hemler, 1990). While it is theo- 
retically possible to make such deletions of t32 in the germ- 
line of mice (Capecchi,  1989),  deletion of/31 may be lethal 
as in Drosophila (Mackrell et al., 1989). It is clear that dom- 
inant negative receptor mutants can provide insights into re- 
ceptor function in vivo (Amaya et al.,  1991; Ueno et al., 
1991)./31(D130A)  is dominant negative since it forms non- 
functional heterodimers with endogenous a~, leading to sup- 
pression of the endogenous t3t integrin function. In the pres- 
ent study, the partial dominant-negative effects by the mutant 
131(D130A) was seen at the ratio of mutant-to-wild-type/31 
expression of ~ 2:1 based on the mean fluorescent intensity, 
suggesting that the level  of/31 integrins expression is just 
enough to support adhesion and spreading on matrix protein 
in CHO cells.  If the/3~(D130A)  is overexpressed in cells 
with less endogenous t31 integrins (e.g., lymphocytic cells) 
instead of fibroblastic CHO cells, higher mutant-to-wild- 
type ratio and therefore more complete dominant negative 
effects may be obtained. This suggests that tissue-specific ex- 
Takada et at, Asp  ~~ to Ala Mutation of lntegrin ~  Subunit  919 Figure 8. Immunohistochemieal localization of/31 or ~I(D130A) in adhesion plaques on FN. CHO (a, d, g, and j),/31-CHO (b, e, h, and 
k), or #I(D130A)-CHO (c, f, i, and/) ceils were plated on FN, incubated for 4 h at 37~  and then fixed with methanol as described in 
Materials and Methods. The fixed cells were incubated with primary antibodies  (7E2, a-c; 102DF5, d-f; QE.2E5, g-i; A1A5,j-1), followed 
by incubation with FITC-labeled goat anti-mouse IgG, for 30 min at room temperature.  Bar,  10 t~m. 
pression of dominant-negative/~(D130A) in transgenic ani- 
mals will provide a powerful means to assess the role of/31 
integrins  in the development and function of differentiated 
tissues. 
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